Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Phase of Trial: Phase III
Latest Information Update: 28 Aug 2018
At a glance
- Drugs Lenalidomide (Primary) ; Bortezomib; Bortezomib; Carfilzomib; Dexamethasone
- Indications Multiple myeloma
- Focus Biomarker; Therapeutic Use
- Acronyms ENDURANCE
- 26 Jan 2018 Planned number of patients changed from 756 to 1080.
- 07 Dec 2017 Planned primary completion date changed from 1 Nov 2024 to 1 Nov 2023.
- 13 Oct 2017 Planned primary completion date changed from 1 May 2016 to 1 Nov 2024.